Mark M. Awad

30.3k total citations · 9 hit papers
275 papers, 10.9k citations indexed

About

Mark M. Awad is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mark M. Awad has authored 275 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 211 papers in Oncology, 183 papers in Pulmonary and Respiratory Medicine and 52 papers in Cancer Research. Recurrent topics in Mark M. Awad's work include Lung Cancer Treatments and Mutations (146 papers), Cancer Immunotherapy and Biomarkers (133 papers) and Lung Cancer Research Studies (55 papers). Mark M. Awad is often cited by papers focused on Lung Cancer Treatments and Mutations (146 papers), Cancer Immunotherapy and Biomarkers (133 papers) and Lung Cancer Research Studies (55 papers). Mark M. Awad collaborates with scholars based in United States, Spain and France. Mark M. Awad's co-authors include Alice T. Shaw, Lynette M. Sholl, Mizuki Nishino, Pasi A. Jänne, Biagio Ricciuti, F. Stephen Hodi, Suzanne E. Dahlberg, James Chih‐Hsin Yang, Justin F. Gainor and Hiroto Hatabu and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Mark M. Awad

252 papers receiving 10.8k citations

Hit Papers

Carboplatin and pemetrexed with or without pembrolizumab ... 2013 2026 2017 2021 2016 2018 2016 2020 2013 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
    2016 1.1k citations James Stevenson, Mark M. Awad et al. profile →
  2. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
    2018 670 citations Mark M. Awad, Emiliano Calvo et al. profile →
  3. MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
    2016 493 citations Mark M. Awad, Geoffrey R. Oxnard et al. Journal of Clinical Oncology profile →
  4. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
    2020 491 citations Mark M. Awad, Tibor Csőszi et al. Journal of Clinical Oncology profile →
  5. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
    2013 460 citations Justin F. Gainor, Mark M. Awad et al. Clinical Cancer Research profile →
  6. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
    2020 425 citations Justin F. Gainor, Mark M. Awad et al. profile →
  7. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    2017 369 citations Guillermo de Velasco, Youjin Je et al. Cancer Immunology Research profile →
  8. PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
    2016 361 citations Mizuki Nishino, Mark M. Awad et al. Clinical Cancer Research profile →
  9. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
    2023 67 citations Tina Cascone, Mark M. Awad et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark M. Awad United States 48 7.8k 5.8k 2.4k 1.7k 1.3k 275 10.9k
Scott Gettinger United States 58 10.3k 1.3× 6.8k 1.2× 2.8k 1.2× 1.7k 1.0× 2.8k 2.1× 258 13.2k
Marie Wislez France 47 4.5k 0.6× 4.1k 0.7× 2.0k 0.8× 958 0.6× 1.3k 1.0× 284 8.1k
Laura Q.M. Chow United States 44 9.1k 1.2× 4.6k 0.8× 2.9k 1.2× 1.6k 1.0× 3.0k 2.3× 159 12.4k
Jamie E. Chaft United States 43 7.0k 0.9× 6.4k 1.1× 1.9k 0.8× 1.5k 0.9× 1.0k 0.8× 175 10.2k
Tanguy Y. Seiwert United States 43 7.0k 0.9× 3.8k 0.6× 2.9k 1.2× 1.5k 0.9× 2.5k 1.9× 228 11.1k
Tibor Csőszi United States 22 9.1k 1.2× 5.8k 1.0× 1.3k 0.5× 1.3k 0.8× 1.9k 1.5× 82 10.7k
Robert C. Doebele United States 53 6.1k 0.8× 7.3k 1.3× 4.0k 1.7× 2.3k 1.4× 694 0.5× 250 10.4k
Craig Devoe United States 17 10.3k 1.3× 3.9k 0.7× 2.3k 0.9× 1.3k 0.7× 4.5k 3.4× 47 12.7k
Dung T. Le United States 49 8.5k 1.1× 3.0k 0.5× 1.9k 0.8× 1.8k 1.1× 2.8k 2.1× 197 11.2k
Yoon Kyung Jeon South Korea 53 4.8k 0.6× 3.5k 0.6× 2.3k 1.0× 1.5k 0.8× 1.7k 1.3× 277 9.1k

Countries citing papers authored by Mark M. Awad

Since Specialization
Citations

This map shows the geographic impact of Mark M. Awad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark M. Awad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark M. Awad more than expected).

Fields of papers citing papers by Mark M. Awad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark M. Awad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark M. Awad. The network helps show where Mark M. Awad may publish in the future.

Co-authorship network of co-authors of Mark M. Awad

This figure shows the co-authorship network connecting the top 25 collaborators of Mark M. Awad. A scholar is included among the top collaborators of Mark M. Awad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark M. Awad. Mark M. Awad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Provencio, Mariano, Mark M. Awad, Tina Cascone, et al.. (2024). LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study. Annals of Oncology. 35. S1239–S1240. 9 indexed citations
2.
Awad, Mark M., Tina Cascone, Jonathan Spicer, et al.. (2024). LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study. ESMO Open. 9. 102985–102985. 2 indexed citations
3.
4.
Ricciuti, Biagio, Rohit Thummalapalli, Fabrizio Citarella, et al.. (2024). Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade.. Journal of Clinical Oncology. 42(16_suppl). 8633–8633.
5.
Spicer, Jonathan, Nicolas Girard, Mariano Provencio, et al.. (2024). Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.. Journal of Clinical Oncology. 42(17_suppl). LBA8010–LBA8010. 25 indexed citations
6.
Alessi, Joao V., Adam Price, Allison L. Richards, et al.. (2023). Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(11). e007618–e007618. 5 indexed citations
7.
Cascone, Tina, Mark M. Awad, Jie He, et al.. (2023). LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology. 34. S1295–S1295. 67 indexed citations breakdown →
8.
Awad, Mark M., Patrick M. Forde, Nicolas Girard, et al.. (2023). 1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial. Annals of Oncology. 34. S731–S731. 14 indexed citations
9.
Johnson, Melissa L., Mark M. Awad, Martin Gutierrez, et al.. (2023). OA05.05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study. Journal of Thoracic Oncology. 18(11). S54–S55. 23 indexed citations
10.
Lamberti, Giuseppe, Ayal A. Aizer, Biagio Ricciuti, et al.. (2023). Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRASG12C-Mutant Non–Small-Cell Lung Cancer. JCO Precision Oncology. 7(7). e2200621–e2200621. 12 indexed citations
11.
Rotow, Julia, Jyoti D. Patel, Helena A. Yu, et al.. (2023). Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR -Mutant and RET Fusion-Positive Lung Cancers. Clinical Cancer Research. 29(16). 2979–2987. 26 indexed citations
12.
Wang, Xinan, Biagio Ricciuti, Tom Nguyen, et al.. (2021). Association between Smoking History and Tumor Mutation Burden in Advanced Non–Small Cell Lung Cancer. Cancer Research. 81(9). 2566–2573. 85 indexed citations
13.
Cheng, Michael L., Marina S.D. Milan, Arrien A. Bertram, et al.. (2021). Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. JCO Precision Oncology. 5(5). 726–732. 15 indexed citations
14.
Ricciuti, Biagio, Gonzalo Recondo, Liam F. Spurr, et al.. (2020). Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(15). 4135–4142. 102 indexed citations
15.
Doroshow, Deborah B., Andrew Schmidt, Ziad Bakouny, et al.. (2020). LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS). Annals of Oncology. 31. S1204–S1204. 4 indexed citations
16.
Bahleda, Rastislav, Antoîne Italiano, Cinta Hierro, et al.. (2019). Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clinical Cancer Research. 25(16). 4888–4897. 187 indexed citations
17.
Hu, Yuebi, Bryan C. Ulrich, Julianna Supplee, et al.. (2018). False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clinical Cancer Research. 24(18). 4437–4443. 290 indexed citations
18.
Dagogo‐Jack, Ibiayi, Pablo Martínez, Beow Y. Yeap, et al.. (2018). Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clinical Cancer Research. 25(1). 158–165. 80 indexed citations
19.
Velasco, Guillermo de, Youjin Je, Dominick Bossé, et al.. (2017). Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research. 5(4). 312–318. 369 indexed citations breakdown →
20.
Bahcall, Magda, Taebo Sim, Cloud P. Paweletz, et al.. (2016). Acquired MET D1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discovery. 6(12). 1334–1341. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott Gettinger Breakdown of academic impact, for papers by Marie Wislez Breakdown of academic impact, for papers by Laura Q.M. Chow Breakdown of academic impact, for papers by Jamie E. Chaft Breakdown of academic impact, for papers by Tanguy Y. Seiwert Breakdown of academic impact, for papers by Tibor Csőszi Breakdown of academic impact, for papers by Robert C. Doebele Breakdown of academic impact, for papers by Craig Devoe Breakdown of academic impact, for papers by Dung T. Le Breakdown of academic impact, for papers by Yoon Kyung Jeon
Rankless by CCL
2026